Sunfox
Strengthening India’s cardiac health through timely intervention
CURRENT IMPACT
As on August 2023
1,347
Spandan ECG devices deployed
53,000+
Patients directly screened through Spandan ECG devices
Samridh support
With SAMRIDH’s support , Sunfox aims to reduce cardiac morbidity and mortality throughout the nation by lowering the cost of the device, establishing the use of early ECG, making ECG a home care device for known cardiac patients and those who are predisposed to developing cardiac diseases.
African Presence
Sunfox has established their presence in 12 countries on the African subcontinent through its intervention Spandan ECG. They have established an active and prospective channel of medical device suppliers and doctors in these countries who have made it possible for Spandan to start the process of medical device compliance certification. So far, there are over 400 Spandan ECG deployed in the African continent actively being used at homes, clinics and medical campaigns and have conducted over 10,000 tests. Sunfox has registered Spandan ECG with the Kenya Pharmacy Board. They are now working on registering the product in other African countries as well. Sunfox has also partnered with United Pharma in Kenya, Global Lifecare in Tanzania and Faryar Pharma Ltd. Mogadishu in Somalia for deployment of Spandan ECG units.
Geographical Focus
- Uttar Pradesh, Uttarakhand, Jammu & Kashmir and Delhi
Potential Impact
- – Reach
1 million
lives - –
0.65 million
ECG tests to be done - – Deploy
500
Spandan ECG devices in semi-urban areas of Tier 1 cities - – Onboard Spandan ECG devices in
1,000
clinics and small hospitals in Tier 2 / 3 cities.
Rajat Jain Chief Executive Officer, Sunfox technologies
Through their avant-garde blended finance model, SAMRIDH enabled us to harness innovation and sustainability, and helped our company attain self-sufficiency by deploying Spandan devices in small towns, clinics, public sector health facilities, and homes. SAMRIDH’s support towards operational expenses and marketing has increased our product visibility and demand, creating opportunities for large-scale sales and deployment through collaboration with state governments, NGOs, home diagnostic, and pharmacy players.
We are grateful for SAMRIDH’s unwavering dedication to driving social impact, which has turbocharged our mission and turned us into agents of change. Together, we are revolutionizing the way the world thinks about healthcare and leaving an indelible mark on humanity. Empowered by SAMRIDH, Sunfox is transcending boundaries and delivering life-saving ECG technology to even the most remote, grassroots communities across the globe.
32
%
of the global deaths are due to cardiovascular diseases in 2019
25,000
deaths due to heart attacks in India consistent since last four years
Less than 20% of hospitals in India have advanced equipment for detecting arrhythmia or coronary heart disease. An early electrocardiogram (ECG) is a simple test that can be used to diagnose cardiac disease and save lives by allowing for timely and effective treatment. Millions of lives lost to cardiovascular diseases may be prevented if round-the-clock monitoring equipment, routine monitoring, and cardiac evaluation were accessible.
Spandan ECG
Sunfox aims to diagnose life-threatening cardiac events in patients within the “golden hour” and work on preventing such events by routine monitoring with their cost-effective device called Spandan ECG at the most remote locations in the country. Spandan will be made readily available across the country, including most neglected and vulnerable communities, with the objective of making home ECG and routine cardiac tracking a reality by making the devices affordable and ensuring reliable tele-reporting of the ECGs.
Key Stakeholders
